Literature DB >> 22843902

Clinical significance of chemoradiotherapy and surgical resection for cT4 esophageal cancer.

Masaru Morita1, Yasushi Toh, Hiroshi Saeki, Masahiko Sugiyama, Kippei Ohgaki, Shin-Ichiro Maehara, Kazuhito Minami, Yasuharu Ikeda, Yoshihisa Sakaguchi, Takeshi Okamura, Satoru Uehara, Yoshihiko Maehara.   

Abstract

AIM: To clarify the clinical significance of definitive chemoradiotherapy (CRT) and CRT followed by esophagectomy for cT4 esophageal cancer. PATIENTS AND METHODS: The treatment results for cT4 esophageal cancer were examined in 81 patients who received definitive CRT [radiation 50-70 Gy, cisplatin and 5-fluorouracil; group I] and 19 patients who underwent esophagectomy after preoperative CRT [40Gy, Group II].
RESULTS: Among the 81 patients in group I, toxicities (grade 3 or 4) were observed in 32 patients, while partial response and complete response were recognized in 8 and 47 patients, respectively. Of the 19 group II patients, an R0 resection was performed in 16 patients, and the mortality rate was 5%. The 5-year survival rates were 19% and 42% in groups I and II, respectively.
CONCLUSION: Long-term survival can be expected after multimodal therapy, even for patients with cT4 esophageal cancer. Esophagectomy is therefore a valid treatment option when down-staging can be achieved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843902

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Surgical treatments for esophageal cancers.

Authors:  William H Allum; Luigi Bonavina; Stephen D Cassivi; Miguel A Cuesta; Zhao Ming Dong; Valter Nilton Felix; Edgar Figueredo; Piers A C Gatenby; Leonie Haverkamp; Maksat A Ibraev; Mark J Krasna; René Lambert; Rupert Langer; Michael P N Lewis; Katie S Nason; Kevin Parry; Shaun R Preston; Jelle P Ruurda; Lara W Schaheen; Roger P Tatum; Igor N Turkin; Sylvia van der Horst; Donald L van der Peet; Peter C van der Sluis; Richard van Hillegersberg; Justin C R Wormald; Peter C Wu; Barbara M Zonderhuis
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

2.  Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Hiroki Harada; Keishi Yamashita; Chikatoshi Katada; Hiromichi Ishiyama; Takafumi Soeno; Marie Washio; Mikiko Sakuraya; Hideki Ushiku; Masahiro Niihara; Kei Hosoda; Naoki Hiki
Journal:  Langenbecks Arch Surg       Date:  2020-07-15       Impact factor: 3.445

Review 3.  Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review.

Authors:  Xiao-Feng Duan; Peng Tang; Zhen-Tao Yu
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

4.  A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.

Authors:  Tianyan Ding; Cantong Liu; Binliang Huang; Lingyu Chu; Laifeng Wei; Yiwei Lin; Yun Luo; Biao Zhang; Chaoqun Hong; Yiwei Xu; Yuhui Peng
Journal:  Cancer Manag Res       Date:  2021-10-09       Impact factor: 3.989

5.  A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.

Authors:  Tian Zhang; Zhoubo Guo; Xi Chen; Jie Dong; Hongjing Jiang; Peng Tang; Ping Wang; Dong Qian; Wencheng Zhang; Qingsong Pang
Journal:  Radiat Oncol       Date:  2022-08-23       Impact factor: 4.309

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.